| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Isoformononetin targets immune cells and bone metabolism pathways. It inhibits the differentiation of Th17 cells and B-cell lymphopoiesis, suggesting activity on T-helper cell differentiation and B-cell development. The compound promotes osteogenesis in estrogen-deficient bone loss conditions, indicating activity on bone-forming cells (osteoblasts) and bone remodeling pathways. As a daidzein analog, it may interact with estrogen receptors or other nuclear receptors involved in bone metabolism and immune function.
|
|---|---|
| ln Vitro |
In vitro, Isoformononetin exhibits immunomodulatory activity. It inhibits the differentiation of Th17 cells and B-cell lymphopoiesis, indicating immunosuppressive effects on specific immune cell populations. The compound promotes osteogenesis in estrogen-deficient bone loss conditions, suggesting bone anabolic activity. As a daidzein analog, it may share similar activities with other isoflavones, including estrogenic or anti-estrogenic effects. However, detailed IC₅₀ values are not extensively published.
|
| ln Vivo |
In vivo, Isoformononetin promotes osteogenesis in estrogen-deficient bone loss conditions. This suggests that the compound may be effective in preventing or treating osteoporosis, particularly in postmenopausal estrogen deficiency. The immunomodulatory effects on Th17 and B-cell differentiation may contribute to its effects on bone metabolism, as these immune cells are involved in the regulation of bone remodeling. However, detailed in vivo study data are not extensively published.
|
| Enzyme Assay |
In vitro assays for Isoformononetin typically involve evaluation of immune cell differentiation. Th17 cell differentiation can be assessed in T-cell culture systems using flow cytometry to detect IL-17-producing cells. B-cell lymphopoiesis can be evaluated in B-cell culture systems using flow cytometry or ELISPOT assays. Osteogenesis can be assessed in osteoblast cultures using alkaline phosphatase staining, mineralization assays (Alizarin Red), and measurement of osteogenic marker gene expression.
|
| Cell Assay |
In vitro cellular assays for Isoformononetin typically involve immune cell cultures and osteoblast cultures. For immunomodulatory studies, T-cells or B-cells are treated with the compound and stimulated with appropriate activating signals, and differentiation is assessed by flow cytometry or cytokine production assays. For osteogenesis studies, osteoblast precursor cells are treated with the compound and osteogenic differentiation is evaluated. Cytotoxicity is assessed using standard cell viability assays.
|
| Animal Protocol |
In vivo animal experiments for Isoformononetin would typically involve ovariectomized rodent models of estrogen-deficient bone loss. The compound is administered orally or intraperitoneally, and endpoints include bone mineral density measurement by DEXA, bone histomorphometry, serum markers of bone turnover (e.g., osteocalcin, CTX-1), and immune cell profiling. However, detailed experimental protocols are not extensively published in the available literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Isoformononetin are characteristic of isoflavone compounds. The compound has a molecular weight of 268.26 g/mol and molecular formula C₁₆H₁₂O₄. As a lipophilic isoflavone, it is expected to have good oral absorption and tissue distribution. Like other isoflavones, it may undergo enterohepatic circulation and metabolism by gut microbiota. Storage: powder at -20°C for 3 years or 4°C for 2 years; in solvent at -80°C for 6 months or -20°C for 1 month.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Isoformononetin is not extensively documented. As an isoflavone analog of daidzein, it is expected to have a safety profile similar to other dietary isoflavones, which are generally considered safe at moderate doses. However, comprehensive toxicological evaluations including acute toxicity, genotoxicity, and reproductive toxicity studies have not been reported. Standard laboratory safety precautions should be followed.
|
| References | |
| Additional Infomation |
Isoflavone glycosides are methoxy isoflavones with hydroxyl and methoxy groups substituted at the 4' and 7' positions, respectively. They possess functions as metabolites, bone mineral density maintainers, and apoptosis inhibitors. They are hydroxy isoflavones belonging to the 7-methoxy isoflavone class of compounds. Their function is related to daidzein. Isoflavone glycosides have been reported to be found in soybean (Glycine max), kudzu root (Pueraria montana var. lobata), and other organisms with relevant data.
Isoformononetin (CAS# 486-63-5, molecular formula C₁₆H₁₂O₄, molecular weight 268.26) is a daidzein analog with immunoprotective effects. It inhibits Th17 and B-cell differentiation and promotes osteogenesis in estrogen-deficient bone loss conditions. Also known as 4'-hydroxy-7-methoxyisoflavone. No clinical trials or regulatory approvals have been identified. Storage: powder at -20°C for 3 years. |
| Molecular Formula |
C16H12O4
|
|---|---|
| Molecular Weight |
268.2641
|
| Exact Mass |
268.074
|
| CAS # |
486-63-5
|
| Related CAS # |
Isoformononetin-d3
|
| PubChem CID |
3764
|
| Appearance |
White to off-white solid
|
| Melting Point |
218 - 220 °C
|
| LogP |
3.174
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
395
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C([H])=C(C2C([H])=C([H])C(=C([H])C=2[H])O[H])C(C2C([H])=C([H])C(=C([H])C1=2)OC([H])([H])[H])=O
|
| InChi Key |
LNIQZRIHAMVRJA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H12O4/c1-19-12-6-7-13-15(8-12)20-9-14(16(13)18)10-2-4-11(17)5-3-10/h2-9,17H,1H3
|
| Chemical Name |
3-(4-hydroxyphenyl)-7-methoxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 250 mg/mL (931.93 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.75 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.75 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7277 mL | 18.6386 mL | 37.2773 mL | |
| 5 mM | 0.7455 mL | 3.7277 mL | 7.4555 mL | |
| 10 mM | 0.3728 mL | 1.8639 mL | 3.7277 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
